World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 21 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 20 August 2018
Main ID:  NCT02668068
Date of registration: 20/01/2016
Prospective Registration: Yes
Primary sponsor: Jianwu Dai
Public title: A Study on Pneumoconiosis Treated With Whole-lung Lavage Combined With Mesenchymal Stem Cells
Scientific title: A Multicenter, Randomized, Single-blind, Parallel-group Study of Combined Large Volume WLL With Clinical Grade Umbilical Cord Mesenchymal Stem Cells(MSC) Transplantation for Treatment of Pneumoconiosis
Date of first enrolment: January 2016
Target sample size: 80
Recruitment status: Active, not recruiting
URL:  https://clinicaltrials.gov/show/NCT02668068
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).  
Phase:  Phase 1
Countries of recruitment
China
Contacts
Name:     JianWu Dai, Ph.D
Address: 
Telephone:
Email:
Affiliation:  Chinese Academy of Sciences
Name:     Wei Xiong, M.D
Address: 
Telephone:
Email:
Affiliation:  First Affiliated Hospital of the Third Military University, PLA (Southwest Hospital)
Name:     Xiaotian Dai,, M.M
Address: 
Telephone:
Email:
Affiliation:  First Affiliated Hospital of the Third Military University, PLA (Southwest Hospital)
Name:     Shencun Fang, M.M
Address: 
Telephone:
Email:
Affiliation:  Nanjing Chest Hospital
Name:     Yingming Zhang, M.M
Address: 
Telephone:
Email:
Affiliation:  Nanjing Chest Hospital
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Male or female, 18-70 years old.

2. Subjects had exposed to dusts with a long history.

3. Subjects with a clear clinical diagnosis to be silicotics or coal miners'
pneumoconiosis patients.

4. Subjects with each detected index of pulmonary function test including FVC, FEV1 or
MVV had exceeded 70% of the predicated value.

5. Subjects signed informed consent.

Exclusion Criteria:

1. Women of childbearing age at the stage of pregnancy or lactation, or those without
taking effective contraceptive measures.

2. Subjects with syphilis or HIV positive antibody.

3. Subjects with infection aggravated within the past month.

4. Subjects suffering from any of the following pulmonary diseases: active tuberculosis,
pulmonary embolism, pneumothorax, multiple huge bullae, uncontrolled asthma, severe
pneumonia, acute exacerbation of chronic bronchitis, AECOPD, severe and / or extremely
severe COPD, etc..

5. Subjects suffering from other serious diseases, such as myocardial infarction,
unstable angina, cirrhosis, and acute glomerulonephritis.

6. Subjects suffering from other life-threatening diseases with an estimated life-span
less than 2 years.

7. Subjects with leukopenia (WBC less than 4x109 / L) or agranulocytosis (WBC less than
1.5x109 / L or neutrophils less than 0.5x109 / L) caused by any reason.

8. Subjects with severe renal impairment, serum creatinine> 1.5 times the upper limit of
normal.

9. Subjects with liver disease or liver damage: ALT, AST, total bilirubin> 2 times the
upper limit of normal

10. Subjects with a history of mental illness or suicide risk, with a history of epilepsy
or other central nervous system disorders.

11. Subjects with severe arrhythmias (such as ventricular tachycardia, frequent
superventricular tachycardia, atrial fibrillation, and atrial flutter, etc.) or
cardiac degree II or above conduction abnormalities displayed via 12-lead ECG.

12. Subjects with a history of alcohol or illicit drug abuse.

13. Subjects accepted by any other clinical trials within 3 months before the enrollment.

14. Subjects with poor compliance, difficult to complete the study.

15. Any other conditions that might increase the risk of subjects or interfere with the
clinical trial.

16. Subjects accepted large volume whole-lung lavage treatment previously.



Age minimum: 18 Years
Age maximum: 70 Years
Gender: All
Health Condition(s) or Problem(s) studied
Pneumoconiosis
Intervention(s)
Biological: clinical grade umbilical cord mesenchymal stem cells
Procedure: large volume whole-lung lavage (WLL)
Primary Outcome(s)
Imaging indicator: Quantitative analysis of CT density histograms [Time Frame: 6 months after surgery]
Incidence of Treatment-Emergent Adverse Events (Safety Evaluation) [Time Frame: 6 months]
Secondary Outcome(s)
Clinical Indicator 1: change in blood gas analysis [Time Frame: 6 months]
Clinical Indicator 2: change in MRC chronic dyspnea scale [Time Frame: 6 months]
Clinical Indicator 3: change in St. George's Respiratory Questionnaire (SGRQ) scale [Time Frame: 6 months]
Fibrosis Indicators in lavage fluid: expression levels of TGF-ß1, hydroxyproline, MMP2, MMP9 [Time Frame: 6 months]
Fibrosis Indicators in serum: expression levels of TGF-ß1, hydroxyproline, MMP2, MMP9 [Time Frame: 6 months]
Immunological Indicator in lavage fluid : response level of CD4+ T lymphocyte subsets (Th1/Th2/Th17) [Time Frame: 6 months]
Immunological Indicator in lavage fluid: expression levels of various cytokines including TNF-a, IL1-ß, MIP-1a, TIMP1, PDGF [Time Frame: 6 months]
Immunological Indicator in serum : expression levels of various cytokines including TNF-a, IL1-ß, MIP-1a, TIMP1, PDGF [Time Frame: 6 months]
Immunological Indicator in serum : response level of CD4+ T lymphocyte subsets (Th1/Th2/Th17) [Time Frame: 6 months]
self-evaluation [Time Frame: 6 months]
Secondary ID(s)
CAS-XDA-SH/NCH/IGDB
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Nanjing Chest Hospital
Southwest Hospital, China
Results
Results available:
Date Posted:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history